Risperidone clinical trial phase development?

Here’s a concise view of how risperidone was developed through clinical trial phases, plus how those phases apply to this drug in general.

How risperidone went through clinical trial phases (general pattern)
- Phase I: Safety, tolerability, pharmacokinetics
- Small numbers of healthy volunteers or patients.
- Goals: how the drug is absorbed, distributed, metabolized, excreted; safe dose ranges and initial side effects.

- Phase II: Preliminary efficacy and dose finding
- Several hundred patients with the target condition (e.g., schizophrenia or bipolar mania).
- Goals: find active dose ranges, gather more safety data, refine efficacy signals using scales like PANSS, BPRS, CGI.

- Phase III: Confirmatory efficacy and safety
- Large, multicenter trials (often multiple trials across populations).
- Goals: robust demonstration of efficacy and comprehensive safety data to support regulatory approval.

- Phase IV: Post-marketing surveillance
- After approval, monitoring long-term safety, rare adverse events, and effectiveness in broader real-world use.
- Often leads to labeling updates and additional indications.

Risperidone-specific notes
- Indications studied include schizophrenia, schizoaffective disorder, and manic/mixed episodes in bipolar disorder; later expanded into pediatric uses (e.g., irritability in autism) via Phase II/III pediatric trials and regulatory approvals.
- Safety considerations that were key in trials included extrapyramidal symptoms, prolactin elevation, weight/metabolic effects, and sedation.

If you’d like, I can provide more precise dates or identify the major pivotal Phase III trials and their findings. Just say if you want a historical timeline or specifics by indication.